Novel systemic lupus erythematosus autoantigens identified by human protein microarray technology

Area of Science:

• Immunology
• Autoimmunity
• Biomarker Discovery

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations.
• Current autoantibody biomarkers for SLE often lack sufficient specificity or sensitivity for accurate diagnosis.
• There is a need for novel autoantibodies to improve SLE detection and management.

Purpose of the Study:

• To screen for novel autoantibodies associated with SLE using a high-throughput protein microarray.
• To validate the diagnostic potential of identified autoantibodies in an expanded patient cohort.
• To investigate the correlation between novel autoantibodies and SLE disease activity.

Main Methods:

• Protein microarray analysis of sera from 30 SLE patients and 30 healthy controls, profiling 5011 human proteins.
• ELISA-based verification of candidate autoantibodies in a larger cohort (110 SLE patients and 471 patients with other autoimmune diseases).
• Statistical analysis to assess diagnostic accuracy and correlation with clinical parameters like SLEDAI score.

Main Results:

• Four candidate autoantibodies were identified using protein microarray screening.
• Anti-CLIC2 autoantibodies showed a significantly higher positive rate (28.18%) in SLE patients compared to non-AD, RA, and SSc patient groups.
• The presence of anti-CLIC2 autoantibodies correlated positively with SLE disease activity (SLEDAI score).

Conclusions:

• Anti-CLIC2 autoantibodies represent a promising novel biomarker for SLE.
• These autoantibodies demonstrate potential for improved diagnostic specificity in SLE.
• Anti-CLIC2 autoantibodies may serve as indicators of SLE disease activity.